MedTrace Logo

Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma

NCT00263484 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2011-07-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether lower than conventional doses of dexamethasone and thalidomide; and a higher dosing frequency of zoledronic acid are effective in the treatment of newly-diagnosed multiple myeloma.

Conditions

Interventions

DRUG

dexamethasone

20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.

DRUG

thalidomide

100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.

DRUG

zoledronic acid

4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Singapore General Hospital

    collaborator OTHER

  • National Cancer Centre, Singapore

    collaborator OTHER

  • Tan Tock Seng Hospital

    collaborator OTHER

  • Seoul National University Hospital

    collaborator OTHER

  • Asan Medical Center

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • Chonnam National University Hospital

    collaborator OTHER

  • Christian Medical College, Vellore, India

    collaborator OTHER

  • Tata Memorial Hospital

    collaborator OTHER_GOV

  • Gleneagles Hospital

    lead OTHER

Principal Investigators

  • Gerrard Teoh, MD · Gleneagles Hospital, Singapore

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-10-31
Completion
2010-10-31

Countries

  • India
  • Singapore
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00263484 on ClinicalTrials.gov